Highlights:
- This implies that persons who have been vaccinated with Covaxin will not need to self-isolate after arriving in England.
- The changes will come into effect from 22nd Nov.
- Covaxin from Bharat Biotech is one of the two major Covid-19 vaccines currently in use in India.
Covid-19 vaccine by Bharat Biotech’s Covaxin has been included in the UK government’s list of authorised coronavirus vaccines for international travellers. This comes barely a week after the WHO authorised the Covid-19 vaccine, Covaxin, developed in India, for emergency use. The changes will go into effect on November 22 at 4 a.m.
This implies that persons who have been immunised with Bharat Biotech’s Covaxin, one of the two main Covid-19 vaccines used in India, would not be required to undergo self-isolation upon arriving in England.
Covishield, an Oxford-AstraZeneca COVID-19 vaccine produced in India by the Serum Institute of India (SII), was added to the UK’s authorised list last month.
On Monday, Alex Ellis, the British High Commissioner to India, posted on Twitter, “More good news for Indian travellers to the UK. From 22 November travellers fully vaccinated with a COVID19 vaccine recognised by WHO for Emergency Use Listing, including Covaxin, will not have to self-isolate; so joining those fully vaccinated with Covishield.”
More good news for ?? travellers to ???
— Alex Ellis (@AlexWEllis) November 8, 2021
From 22 November travellers fully vaccinated with a #COVID19 vaccine recognised by @WHO for Emergency Use Listing, including Covaxin, will not have to self-isolate; so joining those fully vaccinated with Covishield.https://t.co/UyJsryBd0O https://t.co/mZhaqRgB35
In addition to Covaxin, the UK government will add China’s Sinovac and Sinopharm, both of which are on the WHO Emergency Use List, to its authorised Covid vaccine list for inbound travellers.
Also Read: Seven Countries To Participate In India’s NSA Meet On Afghanistan; China, Pakistan To Skip
The UK government has also made it easier for all under-18 visiting England. They will now be considered as fully vaccinated at the border and will be exempt from self-quarantine requirements on arrival, pre-departure testing and day-8 testing. If they test positive, they will only be needed to do one post-arrival test and a confirming free PCR test.
Travellers vaccinated with Bharat Biotech’s Covaxin can enter United States:
Meanwhile, the United States has allowed visitors who have gotten both doses of Covaxin to have permission to enter the country effective from November 8.
On Wednesday, the US Centers for Disease Control (CDC) recognized the WHO decision to provide emergency use listing (EUL) to India’s homegrown vaccine Covaxin, developed by Bharat Biotech.
The World Health Organization (WHO) stated in a tweet that the WHO Technical Advisory Group concluded that the COVID-19 vaccine manufactured by Hyderabad-based Bharat Biotech meets WHO standards for COVID-19 protection.
Australia adds Bharat Biotech’s Covaxin to the list of approved vaccines:
The Australian government has added Covaxin to its list of authorised COVID-19 vaccines, allowing more people to enter the country without being quarantined. In addition to Covaxin, Sinopharm’s BBIBP-CorV vaccine has been authorised.
This will have a substantial influence on foreign student return and skilled and unskilled workers travel to Australia.
